Latest 22 News in the Life Sciences Industry
GlobeNewswire
Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK
11 Jun 2026
GlobeNewswire
Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity
07 Jun 2026
GlobeNewswire
Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care
03 Jun 2026
GlobeNewswire
Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke
26 May 2026
GlobeNewswire
The hidden impact of veterinary care: new insights from a global survey of veterinarians
25 May 2026
GlobeNewswire
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
22 May 2026
GlobeNewswire
CHMP issues positive opinion for JASCAYD® (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU
22 May 2026
GlobeNewswire
Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)
22 May 2026
GlobeNewswire
Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class
22 May 2026
GlobeNewswire
Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026
21 May 2026
PR Newswire Association LLC.
For the Reasons that Matter: A Multi-Spotlight Campaign Puts Adult Respiratory Health in Focus
07 May 2026
PR Newswire Association LLC.
For the Reasons that Matter: A First‑of‑Its‑Kind Multi-Country Campaign Spotlights Adult Respiratory Health
30 Apr 2026
PR Newswire Association LLC.
Quest International Expands European Service Footprint with New ISO Registered Service Repair Center and Warehouse in Bornem, Belgium
22 Apr 2026
PR Newswire Association LLC.
Wegovy®▼(semaglutide injection) 2.4 mg recommended by NICE to reduce risk of major adverse cardiovascular events, including heart attacks and strokes, in adults with established cardiovascular disease and overweight or obesity (BMI ≥27 kg/m2)[1]
01 Apr 2026
Latest News All News
Upcoming Events All Events
- June 2026
- San Diego: RESI San Diego 2026
- San Diego: BIO 2026
- July 2026
- Taipei: BIO Asia-Taiwan